Sciele Pharma And Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results Of Clonicel For ADHD

Sciele Pharma, Inc. (NASDAQ:SCRX) and Addrenex Pharmaceuticals announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel^ for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) showed statistically significant improvement over placebo.